DOCSLIB.ORG

Brian F King and Andrea Townsend- Nicholson University College

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brian F King and Andrea Townsend- Nicholson University College BrianFKingandAndreaTownsend- P2XReceptors Nicholson P2Xreceptors(P2XRs)areligand-gatedion-channels (LGICs)widelydistributedamongstvarioustissue UniversityCollegeLondon,GowerStreet, types,includingautonomic,central,entericand London,WC1E6BT,UK. sensoryneurons,cochlearandretinalcells, endotheliumandepithelium,vascularandvisceral BrianKingisaSeniorLecturerinthe smoothmuscle,heartanddevelopingskeletal DepartmentofPhysiology,andAndrea muscle,bone,haemopoieticcells.TheseLGICsserve Townsend-NicholsonaLecturerinthe tocontroltheexcitabilityoftheirhostcellsthrough DepartmentofBiochemistryandMolecular twoprocesses:i)influxofextracellularsodiumionsto elicitdepolarisation,andii)influxofextracellular Biology.Theyshareacommoninterestin calciumionstoactivateinternalenzymes. purinesignallingatrecombinantandnative P1andP2receptorsandhaveworked P2XRassembly togetheroverthelastsevenyearsonthe Sevenbuildingblocks, orsubunitproteins,are isolationandcharacterisationofnucleotide involvedintheconstructionofP2XRs.Theseseven receptors. buildingblocks–theP2X17toP2Xsubunits–have beenclonedfromhumanandratcDNAlibrariesand, insomecases,alsofrommouse,guinea-pig,chick andzebrafishlibraries.1,2 Fewstructuraldifferences havebeennotedbetweenspeciesorthologuesofthe Introduction sameP2Xsubunit.However,thedegreeofhomology canbeaslittleas27%betweendifferentsubunitsof Extracellularnucleotidesignallingmolecules,suchas thesamespecies.1 Furthermore,theP2Xgenesare ATP,ADP,UTPandUDP,workthroughspecific complexand,duringtranscription,canundergo ionotropic(P2X)ormetabotropic(P2Y)cell-surface alternativesplicingwhich,subsequently,generates receptors.Theuseofanyligandasasignalling variantsubunitproteinsthatareeithernon-functional, moleculenecessitatesamechanismforits dominantnegativeormodulatory. inactivationandso,purinenucleotidesarehydrolysed toadenosine,anucleosidethatactsthrough Eachofthesubunitproteinscanformhomomeric metabotropicadenosine(P1)receptorsubtypes,to P2XRassemblies,althoughthereappeartobe exertphysiologicaleffectsinalmostallorgan difficultiesformingP2Xreceptors3 andP2X systems.Inosine,formedbythedeaminationof 56 receptors.4 Forsuchdifficulties,post-translational adenosine,hasalsobeenshowntohaveagonist modificationofsubunitproteins–particularly activityatnucleosidereceptors.Furthermore, glycosylation–hasastronginfluenceonthe dinucleotidesaresignallingmoleculesintheirown functionalityofmembrane-traffickedP2XRs.5,6,7 Itis right–notonlyatP2receptors,butalsoatspecific currentlybelievedthateitherthreeorsixglycosylated ApAreceptors–and,throughdegradation,can n subunitsmakeafunctionalP2XR,byformingeithera generatenucleosidesandnucleotidestobroaden stretchedtrimerorahexamerofconjoinedtrimers.2,8 theirextracellulartargets. Inadditiontohomomericassembliesofidentical subunits,P2Xproteinsalsoformheteromeric SevenP2X,eightP2Yandfouradenosinereceptor assembliesbyusingtwoorthreebuildingblocks. proteinshavebeenclonedandcharacterised.Despite WheretwoP2Xsubunitsareinvolved, theubiquityofbothpurinergicligandsand immunoprecipitationstudieshavepredictedupto11 purinoceptors,thedifferentialexpressionof heteromericreceptorsubtypes.9 Here,aninteresting purinoceptorsubtypesandligand-metabolising patternhasemerged–P2Xsubunitsaremost enzymesallowsforthegenerationofveryspecific 7 discerningandonlywillformhomomericreceptors, physiologicalresponsesinparticularcelltypesor whereasP2Xsubunitsaremostpromiscuousand tissues.Itisforthisreasonthatnucleotideand 5 willheteropolymerizewithallP2Xsubunits(except nucleosidereceptorshavenowbecometherapeutic P2X).OtherP2Xsubunitscanpolymerisewithsome, targetsforthetreatmentofconditionsasdiverseas 7 butnotall,P2Xsubunits.Asyet,noonehas pain,urinaryincontinence,strokeanddepression, undertakenasystematicstudyofheteromeric andthefieldofpurinoceptorresearchhasexpanded assembliesinvolvingthreedifferentsubunits, significantlyinthelasttenyears.Inthisbriefreview, althoughsuchassembliesmustsurelyoccurinnative weexamineanumberofthepharmacologicaltools tissues,sinceanumberoftissues(e.g.dorsalroot currentlyavailableforthestudyofnucleotideand ganglia,autonomicgangliaandsmoothmusclecells) nucleosidereceptors. possessinabundancetranscriptsandproteinsfor severalP2Xsubunits. TocrisCooksonLtd.,UK TocrisCooksonInc.,USA Tel:+44(0)1179826551 Tel:(800)421-3701 Fax:+44(0)1179826552 Fax:(800)483-1993 [email protected] [email protected] [email protected] www.tocris.com [email protected] Figure1.Thepurinoceptorfamilyofcell-surfacereceptors Thepurinoceptorfamily,atthispointintime,comprises5structurallyandpharmacologicallydistinctgroups–the adeninereceptorgroup(AdenR),adenosinereceptors(ARs),metabotropicnucleotidereceptors(P2YRs), ionotropicnucleotidereceptors(P2XRs)intheirhomomericandheteromericforms,anddinucleotidereceptors (ApnnAR).Thelastgroup(ApARs)mighteventuallybesubdividedintoionotropicandmetabotropicsubgroups,for whichthereispharmacological,butnotyetstructural,evidence.Finally,membersoftheARandP2YRgroups appeartoheterodimerise,althoughonlytheA11/Ycomplexhasbeenstudiedfunctionally. The“purinergic”family AdenRARsP2YRsP2XRsApnARs 1R A1AAA2A2B 3 ? A11/Y YYYYY124611Y12YY1314 X1XXXXXX234567 XXXXX1/22/32/61/54/6 Todate,sevenhomomericP2XRs(P2X17toP2X)and itself.NeitherADPnorAMP(whenpurifiedof fiveheteromericassemblies(P2X1/2,P2X1/5,P2X,2/3 contaminatingATP)willactivateP2Xreceptors, P2X2/6andP2X4/6)havebeencharacterisedbytheir exceptathomomericassembliesofP2X1 splice biophysicalandpharmacologicalproperties. variants(exon6deleted)whichareactivatedbyADP 14 OperationaldifferencesbetweenmanyoftheseP2XR andnotATP,andathomomericP2X7 receptors assembliesaresurprisinglysubtle.Also,mosttissues whichwillrespondtobothADPandAMP(withina expressbothhomomericandheteromericP2XRsofa periodoftime)afterbeingactivatedfirstbyATP.15 The similarpharmacologicalnature.Asaresult,itisan naturally-occurringdiadenosinepolyphosphates inordinatelydifficultprocesstodeterminetheidentity (ApnA,n=3-7)andclosely-relateddinucleotides ofnativeP2XRs.Atthispointintime,itisinadvisable (ApnG,n=3-6)alsoactivateP2XRs,butnonewith tocategorisenativeP2XRsasP2X,123P2X,P2X,etc. eitherthepotencyorefficacyofATP.Membersofthe and,instead,theyshouldbeassociatedwitha diadenosinepolyphosphatefamilyaresoclosein particularphenotype(e.g.P2X123-like,P2X-like,P2X- potencyandefficacyatP2Xassembliesthatthese like,etc.).TherolesofseveralP2Xreceptorsubunits substancescannotbeusedreliably(andalone)as innativechannelshavebeenexaminedbythe discriminatorsofP2Xsubtypes.Thediphosphates, generationofknockoutmice.Nullmutationsforthe Ap22AandApG,arenotagonistsatP2XRs,inkeeping 101112 P2X1,P2X37andP2Xsubunits,and withtherelativeinactivityofADP. 13 overexpressingP2X1 transgenicmice,havebeen described,implicatingP2Xreceptorsinprocessesas AmongstrecombinantP2XRs,thepotencyofATPcan diverseasfertility,thrombosis,painandcytokine varyenormously,withEC50 valuesrangingfrom50 production.invivo nMto300mM,dependingonsubunit composition.1,2,16-20 Althoughmutationalanalyses P2XRagonism havebeencarriedout,astructuralbasishasnotbeen AlloftheknownP2Xassembliesareactivatedby clearlyestablishedforthisobservedvariabilityin ATP,whichisthemostpotentofthenaturally- agonistpotency.AcommonATPrecognitionsitehas 2122 occurringnucleosidetriphosphates(NTPs).Other beenmappedforP2X12andP2Xsubunits,and NTPscanworkatcertainreceptorsubtypes(e.g.CTP thissiteissharedbytheremainingP2Xsubunits. atrecombinantP2X,1P2X4andP2X,55GTPatP2X, However,othermodulatoryfactorsmustclearlycome andUTPatP2X3),butnoneareaspotentasATP intoconsideration.Forinstance,agonistpotencyis 2 Table1.KeyligandsforhomomericP2Xreceptors SubtypeAgonistsAntagonistsPotentiatorsInhibitorsReferences (pEC50)(pIC50)(pEC50/pKa)(pIC50i/pK) + rP2X1 ATP(7.0)NF449(9.5) –H(6.3)1,2,3,17-20, 2-MeSATP(7.0) NF279(7.7) Zn2+ (6.0)25-30,88,89 ATPgS(6.2)NF023(6.7) Gd3+ (6.5) Ap6A(6.0) Suramin(5.7) ApG65(5.7)IpI(8.5) ab,-meATP(5.5)TNP-ATP(9.0) Bz-ATP(4.6)MRS2257(8.3) CTP(4.4)MRS2159(8.0) PPNDS(7.8) PPADS(6.9) RB-2(5.7) (h*)A-317491(4.9) +3+ rP2X2 ATP(5.3)RB-2(6.4)H(7.1)La(5.0)1,2,3,17-20, 2-MeSATP(5.1)NF279(6.4) Zn2+(5.0)Gd3+ (5.0)25-30,90-94 ATPgS(5.1)BBG(5.9)Cu2+(4.8)Ca2+ (1.1) 2+ Ap4A(4.8)TNP-ATP(5.9)Cd(3.5) ab,-meATP(3.0) PPADS(5.8) Suramin(5.0) (h*)A-317491(4.33) 2++ rP2X3 2-MeSATP(6.7) A-317491(7.6)Zn(5.0)H(6.0)1,2,3,17-20, ATP(5.9)NF279(5.8) Ca2+ (1.8)88,89,95,96 ATPgS(5.9)NF449(5.6) (h*)RB-2(5.9) Ap5A(5.5) Suramin(5.4) ApG5 (5.6) NF023(5.0) ab,-meATP(5.7)TNP-ATP(9.5) UTP(4.0)MRS2257(7.7) MRS2159(6.9) PPADS(6.7) IpI5 (5.5) RB-2(4.3) + rP2X4 ATP(5.4)TNP-ATP(4.8)Ivermectin(6.6) H(6.8)1,2,3,17-20, 2-MeSATP(3.6) BBG(3.9)Cibacronblue (5.5)25-30,97-103 CTP(3.5) Propofol(4.3) (h*)BBG(5.5)Zn2+ (5.9) partialagonist:(h*)PPADS(4.6) Cd2+ (5.0) Ap4A(5.5) ab,-meATP(4.2) 2++ rP2X5 ATP(6.4)PPADS(6.7) Zn(4.4)H(5.5)1,2,3,17-20 2-MeSATP(6.4) TNP-ATP(6.3)Ca2+ (3.0) ATPgS(6.5) Suramin(5.8) Bz-ATP(5.9)RB-2(4.7) ab,-meATP(6.0) Ap4A(6.6) GTP(4.6) CTP(4.3) rP2X6 ATP(6.2)–––7 + rP2X7 BzATP(5.2)BBG(8.0)H(6.1)1,2,3,15, 2-MeSATP(5.0)PPADS(4.3) Cu2+ (6.5)17-20,31-33, ATP(3.4)TNP-ATP(~4.3)Zn2+ (4.9)104 Mg2+ (3.3) (mh*)ADP(2.7)(*)KN-62(7.4) Ca2+ (2.5) (mh*)AMP(2.3)(*)KN-04(~6.0)Halideions (BoldtextdenotescompoundsavailablefromTocris) Potencyindicesforagonists,etc.givenas-log10EC50(pEC50)values.Dataforhuman(hm*)andmouse(*) isoformsaregivenforsomekeyligands. 3 stronglyaffectedinonewayoranotherby P2X47andP2X,showtime-dependentchangesin extracellularH+ions(pH)andextracellularZn2+ ions channelpermeabilityandshiftsinreversal 23,24 atalltheknownP2XRsubtypes.Otherextracellular potential.ThiseffectismostprofoundforP2X7 ions,includingNa+,Ba2+,Ca2+,Cd2+,Cu2+,Mg,2+
Load more

Recommended publications
  • Expression of Purinergic Receptors on Microglia in the Animal Model Of
    www.nature.com/scientificreports OPEN Expression of purinergic receptors on microglia in the animal model of choroidal neovascularisation Lu Li1*, Juejun Liu1, Amin Xu1, Peter Heiduschka2, Nicole Eter2 & Changzheng Chen1 To investigate the efect of P2 receptor on microglia and its inhibitor PPADS on choroidal neovascularization. Forty CX3CR1GFP/+ mice were randomly divided into 8 groups. In addition to the normal group, the rest of groups were receiving laser treatment. The retina and choroid from the second, third, fourth and ffth group of mice were taken in the 1, 4, 7, 14 days after laser treatment. The mice in the sixth and seventh group received intravitreal injection of 2 µl PPADS or PBS respectively immediately after laser treatment. The mice in the eighth group received topical application of PPADS once per day of three days. The mice in sixth, seventh and eighth group received AF and FFA examination on the fourth day after laser treatment. Immunofuorescence histochemical staining and real-time quantitative PCR were used to evaluate P2 expression and its efect on choroidal neovascularization. After laser treatment, activated microglia can express P2 receptors (P2X4, P2X7, P2Y2 and P2Y12). The expression of P2 increased on the frst day after laser damage, peaked on the fourth day (tP2X4 = 6.05, tP2X7 = 2.95, tP2Y2 = 3.67, tP2Y12 = 5.98, all P < 0.01), and then decreased. After PPADS inhibition, compared with the PBS injection group, the mRNA of P2X4, P2X7, P2Y2 and P2Y12 were decreased signifcantly in the PPADS injection group (tP2X4 = 5.54, tP2X7 = 9.82, tP2Y2 = 3.86, tP2Y12 = 7.91, all P < 0.01) and the PPADS topical application group (tP2X4 = 3.24, tP2X7 = 5.89, tP2Y2 = 6.75, tP2Y12 = 4.97, all P < 0.01).
    [Show full text]
  • The Inflammasome Promotes Adverse Cardiac Remodeling Following Acute
    The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Eleonora Mezzaromaa,b,c,1, Stefano Toldoa,b,1, Daniela Farkasb, Ignacio M. Seropiana,b,c, Benjamin W. Van Tassellb,c, Fadi N. Sallouma, Harsha R. Kannana,b, Angela C. Mennaa,b, Norbert F. Voelkela,b, and Antonio Abbatea,b,2 aVCU Pauley Heart Center, bVCU Victoria Johnson Center, and cSchool of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 Edited* by Charles A. Dinarello, University of Colorado Denver, Aurora, CO, and approved October 19, 2011 (received for review May 31, 2011) Acute myocardial infarction (AMI) initiates an intense inflamma- and increased caspase-1–mediated cell death in a more severe tory response that promotes cardiac dysfunction, cell death, and model of ischemia without reperfusion. We also describe phar- ventricular remodeling. The molecular events underlying this macologic inhibition of cryopyrin and P2X7 to prevent inflam- inflammatory response, however, are incompletely understood. masome formation and ameliorate cardiac damage as a potential In experimental models of sterile inflammation, ATP released from basis for translational investigation. dying cells triggers, through activation of the purinergic P2X7 receptor, the formation of the inflammasome, a multiprotein Results complex necessary for caspase-1 activation and amplification of Caspase-1 Is Activated in AMI. Caspase-1 mRNA synthesis in- the inflammatory response. Here we describe the presence of the creased severalfold in the heart at 3 and 7 d after AMI (Fig. S1). inflammasome in the heart in an experimental mouse model of Caspase-1 activation was also increased at 7 d as measured by AMI as evidenced by increased caspase-1 activity and cytoplasmic increased procaspase-1, increased cleaved caspase-1, and in- aggregates of the three components of the inflammasome—apo- creased cleaved/procaspase-1 ratio (Fig.
    [Show full text]
  • SYNTHESIS and BIOLOGICAL Actnnry of CONFORMATIONALLY CONSTRAINED WLEOSIDES and NUCLEOTIDES
    SYNTHESIS AND BIOLOGICAL ACTnnrY OF CONFORMATIONALLY CONSTRAINED WLEOSIDES AND NUCLEOTIDES A thesis submitted in conformity with the requirements for the degree of Masters of Science Graduate Department of Chemistry University of Toronto National Library Bibliothèque nationaie B*m ofCanada du Canada Acquisitions and Acquisitions et Bibliographie Setvices services bibliographiques 395 Wellington Street 395. rue Wellington ûttawaON K1AW OctawaON KlAW canada canada The author has granted a non- L'auteur a accorde une licence non exclusive Licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distn'buer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/fïlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Spthesis and Biologicai Activity of Conformationaliy Constrained NucIeosides and Nuc1eotides Degree of Master of Science, 1998 by Girolamo Tusa Graduate Department of Chemistry, University of Toronto This thesis outhes the synthesis of a variety of confonnationally constrained nucleosides and nucleotide analogues. The conformationally 'locked" analogues closely resemble specific conformers of natural nucleosides and nucieotides and were used to probe the conformationai specificity of particular physiological processes in PC 12 ce&; nucleoside transport (NT) activity and Pt-purinoceptor response.
    [Show full text]
  • Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CH
    Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CHIBA, M.D., Miyoharu KOBAYASHI, M.D., Masahiro SHIMOTORI,M.D., Yasuyuki FURUKAWA, M.D., and Kimiaki SAEGUSA, M.D. SUMMARY When dilazep was administered intravenously to the anesthe- tized donor dog, mean systemic blood pressure was dose depend- ently decreased. At a dose of 0.1mg/Kg i.v., the mean blood pressure was not changed but a slight decrease in heart rate was usually observed in the donor dog. At the same time, a slight but significant decrease in atrial rate and developed tension of the iso- lated atrium was induced. Within a dose range of 0.3 to 1mg/Kg i.v., dilazep caused a dose related decrease in mean blood pressure, bradycardia in the donor dog, and negative chronotropic, dromo- tropic and inotropic effects in the isolated atrium. At larger doses of 3 and 10mg/Kg i.v., dilazep caused marked hypotension, fre- quently with severe sinus bradycardia or sinus arrest, especially in isolated atria. When dilazep was infused intraarterially at a rate of 0.2-1 ƒÊ g/min into the cannulated sinus node artery of the isolated atrium, negative chrono- and inotropic effects were dose dependently in- duced. With respect to dromotropism, SA conduction time (SACT) was prolonged at infusion rates of 0.2 and 0.4ƒÊg/min. But at 1ƒÊg, dilazep caused an increase or decrease of SACT, indicating a shift of the SA nodal pacemaker. It is concluded that dilazep has direct negative chrono-, dromo- and inotropic properties on the heart at doses which produced no significant hypotension.
    [Show full text]
  • Use of Uridine in Combination with Choline for the Treatment Of
    (19) TZZ ¥ _T (11) EP 2 329 829 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/7072 (2006.01) A61K 31/14 (2006.01) 16.04.2014 Bulletin 2014/16 A61K 31/685 (2006.01) A61P 25/28 (2006.01) (21) Application number: 10075661.8 (22) Date of filing: 30.07.1999 (54) Use of uridine in combination with choline for the treatment of neurological disorders Verwendung von Uridin in Kombination mit Cholin zur Behandlung neurologischer Erkrankungen Utilisation de l’uridine en combinaison avec la choline pour le traitement des maladies neurologiques (84) Designated Contracting States: • CACABELOSR ET AL: "THERAPEUTIC EFFECTS AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU OF CDP-CHOLINE IN ALZHEIMER’S DISEASE MC NL PT SE COGNITION, BRAIN MAPPING, CEREBROVASCULAR HEMODYNAMICS, AND (30) Priority: 31.07.1998 US 95002 P IMMUNE FACTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK (43) Date of publication of application: ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 08.06.2011 Bulletin 2011/23 January 1996 (1996-01-01), pages 399-403, XP008065562, ISSN: 0077-8923 (62) Document number(s) of the earlier application(s) in • SPIERS P A ET AL: "CITICOLINE IMPROVES accordance with Art. 76 EPC: VERBAL MEMORY IN AGING", ARCHIVES OF 09173495.4 / 2 145 627 NEUROLOGY, AMERICAN MEDICAL 07116909.8 / 1 870 103 ASSOCIATION, CHICAGO, IL, US, vol. 53, no. 5, 99937631.2 / 1 140 104 1 May 1996 (1996-05-01), pages 441-448, XP008028412, ISSN: 0003-9942 (73) Proprietor: Massachusetts Institute of Technology • WEISS G B: "Metabolism and actions of CDP- Cambridge, Massachusetts 02142-1601 (US) choline as an endogenous compound and administered exogenously as citicoline.", LIFE (72) Inventors: SCIENCES 1995 LNKD- PUBMED:7869846, vol.
    [Show full text]
  • Long-Term Oral Administration of Dipyridamole Improves Both
    913 Hypertens Res Vol.30 (2007) No.10 p.913-919 Original Article Long-Term Oral Administration of Dipyridamole Improves Both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-Randomized Study Shoji SANADA1),2), Hiroshi ASANUMA3), Yukihiro KORETSUNE4), Kouki WATANABE5), Shinsuke NANTO6), Nobuhisa AWATA7), Noritake HOKI2), Masatake FUKUNAMI2), Masafumi KITAKAZE3), and Masatsugu HORI1) Adenosine is known as an endogenous cardioprotectant. We previously reported that plasma adenosine lev- els increase in patients with chronic heart failure (CHF), and that a treatment that further elevates plasma adenosine levels may improve the pathophysiology of CHF. Therefore, we performed a prospective, open- randomized clinical trial to determine whether or not exposure to dipyridamole for 1 year improves CHF pathophysiology compared with conventional treatments. The study enrolled 28 patients (mean±SEM: 66±4 years of age) attending specialized CHF outpatient clinics with New York Heart Association (NYHA) class II or III, no major complications, and stable CHF status during the most recent 6 months under fixed medica- tions. They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in addition to their original medications and were followed up for 1 year. The other drugs were not altered. Among the enrolled patients, 100%, 4%, 100%, and 79% received angiotensin-converting enzyme inhibitors, aldosterone analogue, loop diuretics, and β-adrenoceptor blocker, respectively. Fifteen patients suffered from dilated cardiomyopathy, and 7/3/3 patients suffered from ischemic/valvular/hyperten- sive heart diseases, respectively. Mean blood pressure was comparable among the groups.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines
    [CANCER RESEARCH 61, 7217–7224, October 1, 2001] Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines Henriette Gourdeau,1,2 Marilyn L. Clarke,1 France Ouellet, Delores Mowles, Milada Selner, Annie Richard, Nola Lee, John R. Mackey, James D. Young,3 Jacques Jolivet, Ronald G. Lafrenie`re, and Carol E. Cass4 Shire BioChem Inc., Laval, Que´bec, H7V 4A7 Canada [H. G., F. O., A. R., N. L., J. J., R. G. L.]; Departments of Oncology [M. L. C., J. R. M., C. E. C.] and Physiology [J. D. Y.], University of Alberta, Alberta T6G 1Z2 Canada; and Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 Canada [M. L. C., D. M., M. S., J. R. M., C. E. C.] ABSTRACT oxycytidine analogues such as gemcitabine (2Ј,2Ј-difluorodeoxycyti- dine; dFdC) and cytarabine (1-␤-D-arabinofuranosylcytosine; araC), -Troxacitabine (Troxatyl; BCH-4556; (-)-2؅-deoxy-3؅-oxacytidine), a de which are in the ␤-D configuration, troxacitabine has a nonnatural ␤-L oxycytidine analogue with an unusual dioxolane structure and nonnatural configuration. Troxacitabine, which shares the same intracellular ac- L-configuration, has potent antitumor activity in animal models and is in clinical trials against human malignancies. The current work was under- tivation pathway as gemcitabine and cytarabine, undergoes a series of taken to identify potential biochemical mechanisms of resistance to trox- phosphorylation reactions through a first rate-limiting step catalyzed 5 acitabine and to determine whether there are differences in resistance by dCK (EC 2.7.1.74) to form the active triphosphate nucleotide.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Suramin As a Chemo- and Radio-Sensitizer
    SURAMIN AS A CHEMO- AND RADIO-SENSITIZER: PRECLINICAL TRANSLATIONAL STUDIES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Yan Xin, M.S. ***** The Ohio State University 2006 Dissertation Committee: Dr. M. Guillaume Wientjes, Adviser Approved by Dr. Jessie L.-S. Au ____________________________________ Adviser Dr. Duxin Sun Graduate Program in Pharmacy ABSTRACT Previous studies in our laboratory showed that low-dose suramin, an inhibitor of fibroblast growth factor action, enhances sensitivity of various human tumors in preclinical and clinical studies to chemotherapy. Chemosensitization required apoptosis, and increased the extent and duration of the induction of apoptosis. The primary focus of this dissertation research was to explore, in preclinical studies, therapeutic approaches for therapy enhancement based on this mechanism. A phase III clinical trial in superficial bladder cancer, which emanated from our laboratory, showed that optimizing mitomycin C delivery nearly doubled the recurrence- free survival of treated patients to 40%. Tumor sensitization with suramin might yield further therapeutic improvements, and was investigated in in vitro and in vivo studies. Studies in Chapter 2 demonstrated enhanced antitumor activity of mitomycin C, administered at subtherapeutic and therapeutic regimens. Various preclinical and clinical studies determined that suramin sensitized tumor tissue at low but not at high concentrations, presumably due to additional pharmacologic effects at elevated concentrations. Studies to overcome this limitation, especially in tumors containing high fibroblast growth factor concentrations, used pentosan polysulfate, another nonspecific FGF inhibitor. This agent was also a chemosensitizer, but combined use with suramin did not increase the overall efficacy (Chapter 3).
    [Show full text]
  • Antidepressant-Like Effects of P2 Purinergic Antagonist PPADS Is Dependent on Serotonergic and Noradrenergic Integrity
    bioRxiv preprint doi: https://doi.org/10.1101/086983; this version posted November 10, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Antidepressant-like effects of P2 purinergic antagonist PPADS is dependent on serotonergic and noradrenergic integrity. Authors: Cassiano R. A. F. Diniza, Murilo Rodriguesb, Plínio C. Casarottoc, Vítor S. Pereirad, Carlos C. Crestanie, Sâmia R.L. Jocab,d*. aSchool of Medicine, Campus USP, Ribeirão Preto, SP 14049-900, Brazil bDepartment of Physics and Chemistry, School of Pharmaceutical Sciences, Campus USP, Ribeirão Preto, SP 14040-904, Brazil. cNeuroscience Center, University of Helsinki, Finland dDepartment of Clinical Medicine - Translational Neuropsychiatry Unit, Aarhus University, Denmark eLaboratory of Pharmacology, School of Pharmaceutical Sciences, UNESP - Universidade Estadual Paulista, Araraquara, SP, Brazil *Corresponding Author: Sâmia Joca. Department of Physics and Chemistry - School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP) University of São Paulo (USP). AvCafe, s/n, 14040-903, Ribeirão Preto - SP, Brazil. Phone: +55-16-33154705 -Fax: +55-16-33154880. e-mail: [email protected] Samia R. L. Joca: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/086983; this version posted November 10, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]